SCHEMBL485950

SCHEMBL485950

CCNc1nc(-c2ccc(NC(=O)NCc3ccc(NC(=O)OC(C)(C)C)nc3)c(F)c2)ccc1C(=O)NCCN1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.45
HDAC1 Q13547 1/20 0.40
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
IKBKB O14920 2/20 0.38
JAK2 O60674 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BDKRB1 P46663 1/20 0.36
CHRNA7 P36544 1/20 0.35
KCNH2 Q12809 1/20 0.35
EPHX2 P34913 2/20 0.35
CD274 Q9NZQ7 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34
SCN9A Q15858 2/20 0.34
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486108 0.90 IKBKB (0.41) NAMPTIKBKBMEN1KMT2ABDKRB1
SCHEMBL3048972 0.90 NAMPT (0.55) NAMPTHDAC1ACHEBACE1JAK2
SCHEMBL486437 0.88 TRPV1 (0.41) NAMPTIKBKBMEN1KMT2ACHRNA7
SCHEMBL485908 0.88 PIK3CA (0.41) NAMPTIKBKBMEN1KMT2ACHRNA7
SCHEMBL485903 0.88 PIK3CA (0.41) NAMPTIKBKBMEN1KMT2ACHRNA7
SCHEMBL722481 0.88 NAMPT (0.41) NAMPTHDAC1TRPV1
SCHEMBL485853 0.87 PIK3CA (0.41) NAMPTIKBKBMEN1KMT2ACHRNA7
SCHEMBL486214 0.86 MEN1 (0.38) NAMPTIKBKBMEN1KMT2ACHRNA7
SCHEMBL485951 0.86 NAMPT (0.45) NAMPTHDAC1BDKRB1TRPV1CDK9
SCHEMBL486093 0.85 PIK3CA (0.39) NAMPTIKBKBMEN1KMT2ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP disclosed
WO-2010109122-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed
WO-2010109122-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS NAMPT, NNT, NQO1 NAMPT 1/4885HDAC1 234/4885ACHE 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.